2011
Zerhouni joined Sanofi as head of R&D in 2011, according to host Luke Timmerman.
“He took his current job at Sanofi in 2011.”
Topic
8 facts from 5 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2011
Zerhouni joined Sanofi as head of R&D in 2011, according to host Luke Timmerman.
“He took his current job at Sanofi in 2011.”
2023
John Reed, who had spent about five years running research and development at Sanofi, left the company and was hired by Johnson & Johnson as its chief scientific officer.
“John Reed, who had spent about five years running the research and development operation at Sanofi, would be leaving the company.”
2024
Dupixent generated about 14 billion euros for Sanofi in 2024.
“In 2024 alone, DuPixent generated about 14 billion euros for the company.”
2025
Sanofi sent Blueprint a written proposal of $124 per share in cash, about $8.5 billion, on January 17, 2025.
“four days later, on January 17th, Sanofi sends a formal written proposal. $124 a share, all cash. That's about $8.5 billion.”
2025
Sanofi's final CVR paid $2 per share on an early-asset clinical milestone and $4 on FDA approval.
“Importantly, the CVR pays out $2 if an early asset hits a clinical milestone and $4 if it ever gets to FDA approval.”
Undated
Emma Walmsley says GSK now has approved COVID-19 vaccines through its partnership with Sanofi.
“In terms of vaccines, we do actually have approved vaccines now in our partnership with Sanofi.”
Undated
Sheller spent about 13 years at Sanofi, then moved to the biotech Kyowa Kirin, and has now been at Merck for over eight years.
“I spent about 13 years at large pharma at Sanofi and went to a small biotech, Keowakirin, shortly thereafter, before coming back into large pharma here at Merck for over eight years.”
Undated
Sanofi settled the Genzyme CVR lawsuit for about 24 cents on the dollar.
“As it turns out, Sanofi ended up settling years later for 24 cents on the dollar.”
Episodes